Characterisation techniques for investigating TBC and EBC failure: a review
Frontiers in Ceramics · 2024
DOI: 10.3389/fceic.2023.1307437 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Ceramics, 2024. Verfasst von Daniel Scotson und 2 weiteren Autor:innen. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 297 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council.
Abstract (Originalsprache)
Materials characterisation plays a crucial role in developing thermal barrier coatings and environmental barrier coatings for gas-turbine engines. The failure of thermal barrier coatings and environmental barrier coatings is influenced by a complex interdependence of microstructure, residual stress, and thermomechanical properties. Validating our mechanistic understanding of each of these factors that contribute to failure requires a selection of suitable characterisation techniques. Presented in this review are characterisation techniques, both ex situ and in situ , that have advanced the understanding of thermal barrier coating and environmental barrier coating failure. Targeted coating development that is both effective and efficient depends on these characterisation techniques to obtain superior coatings with improved performance and lifetime.
Förderung
- Engineering and Physical Sciences Research Council
Zitieren
APA
Scotson, D., Paksoy, A. H., & Xiao, P. (2024). Characterisation techniques for investigating TBC and EBC failure: a review. Frontiers in Ceramics. https://doi.org/10.3389/fceic.2023.1307437
Vancouver
Scotson D, Paksoy AH, Xiao P. Characterisation techniques for investigating TBC and EBC failure: a review. Frontiers in Ceramics. 2024. doi:10.3389/fceic.2023.1307437
BibTeX
@article{Scotson2024,
author = {Scotson, Daniel and Paksoy, Ahmet Hilmi and Xiao, Ping},
title = {Characterisation techniques for investigating TBC and EBC failure: a review},
journal = {Frontiers in Ceramics},
year = {2024},
doi = {10.3389/fceic.2023.1307437}
}
EUVIMED